China-based 3SBio Inc. (HKG: 1530) has announced a strategic partnership with fellow domestic firm Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506). The collaboration aims to advance the exploration of combining 3SBio’s 707 and Sichuan Biokin’s BL-B01D1 for the treatment of solid tumors in mainland China.
Drug Profiles
- 707: Developed by 3SBio using its independent dual antibody platform, 707 is a PD-1 and VEGF bispecific antibody (BsAb). It is currently in Phase II studies for first-line PD-L1 positive non-small cell lung cancer (NSCLC) as a monotherapy and for first-line NSCLC, metastatic colorectal cancer (mCRC), and advanced gynecological tumors (including endometrial and ovarian cancers) in combination with other therapies. 707 has also received clinical approval in the US.
- BL-B01D1: This antibody drug conjugate (ADC) targeting EGFR and HER3 is developed in-house by Sichuan Biokin. It is currently undergoing a total of 30 clinical studies in the US and China across multiple tumor types, including seven Phase III studies as a monotherapy in later-line tumors. In the US, BL-B01D1 is being evaluated in a Phase I study as a monotherapy in multiple solid tumors and in a Phase I/IIa study in advanced solid tumors in combination with osimertinib and pembrolizumab.
Collaboration Details
The partnership between 3SBio and Sichuan Biokin is focused on exploring the combination of 707 and BL-B01D1 as a potential treatment for solid tumors. This collaboration leverages the strengths of both companies in developing innovative therapies for cancer treatment.-Fineline Info & Tech
